Publication | Closed Access

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

OncologyAnti-pd-1 TherapyMelanomaImmunologyClinical TrialsMetastatic MelanomaImmune Checkpoint InhibitorCohort StudyPharmacotherapyCancer TreatmentImmunotherapyMedicineTherapy Resistance